Enable Injections and Incyte Partner to Advance Drug Delivery for Chronic Blood and Bone Marrow Conditions

Enable Injections, the developer of the enFuse wearable drug delivery system, has entered into a strategic partnership with biopharmaceutical company Incyte. The collaboration aims to enhance patient care for chronic blood and bone marrow disorders by combining their respective technologies.

Partnership Details and Focus

The partnership primarily targets Incyte's investigational mutant calreticulin selective monoclonal antibody treatment. This therapy is being developed for two specific conditions:

1. Essential thrombocythemia, a blood disorder
2. Myelofibrosis, a chronic bone marrow disorder

Under the terms of the agreement, Incyte will provide Enable Injections with an upfront technology access fee. Additional payments will be linked to research and development milestones, commercial milestones, and a transfer price for the clinical and commercial supply of enFuse devices.

Technological Advancements in Drug Delivery

Enable Injections' enFuse system represents a significant advancement in drug delivery technology. The system is capable of administering large volumes of both small-molecule and biologic medications subcutaneously. This innovation offers patients a simpler alternative to traditional intravenous administration, allowing for easier at-home treatment through a straightforward injection under the skin.

Bill Meury, Incyte's recently appointed president and chief executive, expressed enthusiasm about the collaboration, stating, "We're looking forward to partnering with Enable and combining our expertise to make advanced treatments more accessible and less burdensome for patients, while maintaining the high standards of safety and efficacy patients and providers expect."

Strategic Moves and Pipeline Updates

This partnership aligns with Incyte's broader business development strategy, as outlined by Meury during the company's second-quarter earnings call. The focus is on acquiring "derisked pre-revenue or revenue-stage opportunities" to bolster Incyte's portfolio.

Concurrent with this announcement, Incyte revealed its decision to discontinue its BET inhibitor program and halt work on the anti-CD122 drug INCA034460. The company described these moves as part of its "ongoing pipeline prioritization efforts," indicating a strategic realignment of its research and development focus.